Strata Critical Medical (SRTA) Depreciation & Amortization (CF) (2021 - 2026)

Strata Critical Medical (SRTA) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 80.32% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $9.5 million (up 57.43% YoY), while the FY2025 annual figure was $8.2 million, up 37.29% from the prior year.
• Depreciation & Amortization (CF) rose to $3.1 million in Q1 2026 per SRTA's latest filing, from $3.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.1 million in Q1 2026 and bottomed at $1.1 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.9 million across 5 years, with a median of $1.7 million in 2025.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 808.73% — and 2024, when it slumped 30.6%.
• Strata Critical Medical's Depreciation & Amortization (CF) stood at $2.3 million in 2022, then slipped by 21.48% to $1.8 million in 2023, then retreated by 15.28% to $1.5 million in 2024, then jumped by 96.6% to $3.0 million in 2025, then increased by 1.73% to $3.1 million in 2026.
• Business Quant data shows SRTA's Depreciation & Amortization (CF) at $3.1 million in Q1 2026, $3.0 million in Q4 2025, and $1.7 million in Q3 2025.